We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » High Court Refusal to Hear Pay-for-Delay Case Opens Door to Antitrust Scrutiny
High Court Refusal to Hear Pay-for-Delay Case Opens Door to Antitrust Scrutiny
The U.S. Supreme Court has paved the way for non-cash patent settlements, which are often reached by branded and generics drugmakers, to trigger antitrust scrutiny after it refused to hear a case involving GlaxoSmithKline’s epilepsy therapy Lamictal.